Stephen Falk

NIHR Bristol Cardiovascular Biomedical Research Unit — United Kingdom

Medicine · Health Sciences

57h-index24.8kcitations220works6.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(67), Esophageal Cancer Research and Treatment(53), Colorectal Cancer Treatments and Studies(52), Pancreatic and Hepatic Oncology Research(43), Lung Cancer Treatments and Mutations(35)

Publications216 total

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
Journal of Clinical Oncology·2026Open Access
Relieving Bowel Obstruction with EUS and Stenting
Global Journal of Medical and Clinical Case Reports·2025Open Access
2186 ARISTOTLE: Mature results of a phase 3 trial evaluating the addition of irinotecan to capecitabine chemoradiation in locally advanced rectal cancer
Radiotherapy and Oncology·2025
Evaluation der spongiösen Knochendichte von C3 bis L5 bei 11 Körperspenden: CT- versus Mikro-CT-Messungen
Osteologie/Osteology·2025
[177Lu]Lu-DOTA-TATE chez les patients nouvellement diagnostiqués atteints de TNE GEP avancées bien différenciées de grade (G)2 et 3 : analyse primaire de NETTER-2
Médecine Nucléaire·2025
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Journal of Clinical Oncology·2024· 19 citedOpen Access
1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study
Annals of Oncology·2024Open Access
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial
European Journal of Cancer·2024· 5 citedOpen Access
71 Stereotactic Ablative Radiotherapy Is a Safe and Feasible Treatment Option for Patients with Hepatocellular Carcinoma
British journal of surgery·2024Open Access
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy
JAMA Surgery·2024· 12 citedOpen Access
211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study
Annals of Oncology·2024· 6 cited
Safety and time to response of [<sup>177</sup>Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.
Journal of Clinical Oncology·2024· 1 cited
Laparoscopic or open abdominal surgery with thoracotomy for patients with oesophageal cancer: ROMIO randomized clinical trial
British journal of surgery·2024· 11 citedOpen Access
StereoTactic ablative radiotherapy provides a safe and feasible treatment alternative for non-surgical candidates with primary hepatocellular carcinoma
European Journal of Surgical Oncology·2024
[<sup>177</sup>Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.
Journal of Clinical Oncology·2024· 45 cited
Standard or High Dose Chemoradiotherapy, with or Without the Protease Inhibitor Nelfinavir, for the Treatment of Locally Advanced Pancreatic Cancer: Efficacy, Safety and Health-Related Quality of Life Outcomes from the Multi-Centre Two Stage Phase 1/Randomised Phase 2 SCALOP-2 Study
SSRN Electronic Journal·2024Open Access
Genetic and immune landscape evolution in <scp>MMR‐</scp> deficient colorectal cancer
The Journal of Pathology·2023· 13 citedOpen Access
HPB P03 Stereoractic ablative radiotherapy provides a safe and feasible treatment alternative for non-surgical candidates with primary hepatocellular carcinoma
British journal of surgery·2023Open Access
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
˜The œLancet. Gastroenterology & hepatology·2023· 156 citedOpen Access
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
EClinicalMedicine·2023· 9 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

David Cunningham(24), Juan W. Valle(15), Jonathan Wadsley(15), Harpreet Wasan(15), Jane Blazeby(15), John Bridgewater(14), Timothy Iveson(12), Paul J. Ross(12), Tim Maughan(11), Gary Middleton(10), Daniel H. Palmer(9), Fareeda Y. Coxon(9), John P. Neoptolemos(8), Tamas Hickish(8), Alan Anthoney(7), Pippa Corrie(7), Gareth Griffiths(7), Jenny Donovan(7), Tom Crosby(6), Yuk Ting(6)